Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
Booking Holdings Shares Slide on Middle East Conflict Impact and Growth Outlook Cut
Booking Holdings shares dropped 4.9% after cutting its full-year revenue growth target to high single digits, citing Middle East conflict impacts. Rivals Expedia and Airbnb also fell.
Delta Flight to Lagos Returns to Atlanta After Eight-Hour Airborne Issue
Delta Flight DL54 from Atlanta to Lagos turned back over the Atlantic after nearly eight hours, citing an operational issue, canceling the return flight and stranding passengers.
Redwire Shares Surge on Record $498M Backlog, Defense Orders in Focus
Redwire shares surged 10% on Monday after reporting a record backlog of $498.1 million, including a $1.8 billion Andromeda contract, and reaffirming its 2026 revenue outlook.
Tesla Shares Climb Despite China Sales Dip on Musk's China Trip Hopes
Tesla shares rose 2.8% despite a 9.66% drop in April China retail sales, as exports surged and Musk's potential China trip with Trump boosted sentiment.
IREN Shares Slide on $2B Convertible Note Sale Amid AI Pivot
IREN Limited shares dropped after the company launched a $2 billion convertible note sale to finance its AI infrastructure buildout, including a major Nvidia cloud deal.
Nokia Stock Climbs on AI Cloud Growth, Investor Optimism Returns
Nokia shares surged 4.1% on Monday, driven by a 49% jump in AI and cloud sales and 1 billion euros in orders, though analysts caution on valuation.
Coterra Energy Delisted After Devon Merger, Combined Entity Targets $1B in Synergies
Coterra Energy shares have stopped trading on the NYSE after Devon Energy completed its all-stock acquisition. Former Coterra holders received 0.70 Devon shares per Coterra share, and the merged firm now trades under DVN.
Pfizer's Recovery Play: Can New Drugs Offset Patent Cliff?
Pfizer stock gains on Q1 beat and steady outlook, but investors weigh patent cliff risks against new oncology and GLP-1 drug prospects.
